This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundPediatric cardiomyopathies are rare but life-threatening conditions with high mortality. ConclusionsThis study underscores the importance of early diagnosis, genetic testing, and integrated management in pediatric cardiomyopathies. Demographic, clinical, and diagnostic data, as well as follow-up outcomes, were reviewed.
Background High-intensity physical activity has traditionally been discouraged in patients with hypertrophic cardiomyopathy due to concerns about triggering sudden cardiac death. However, current guidelines adopt a more liberal stance, and evidence on risk factors for exercise-related sudden cardiac death remains limited.
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
Circulation: Heart Failure, Volume 16, Issue 12 , Page e010351, December 1, 2023. Recent evidence suggests that loss of PRDM16 expression is associated with cardiomyopathy development in mice, although its role in human cardiomyopathy development is unclear.
Viz HCM, the companys AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. tim.hodson Mon, 04/07/2025 - 16:15 April 4, 2025 Viz.ai JACC: Clinical Electrophysiology.
BridgeBio has also presented additional detailed results from ATTRibute-CM at the European Society of Cardiology Congress 2023 in August and at the American Heart Association Scientific Sessions 2023 in November. FDA in 2023 and intends to submit additional marketing authorization applications to regulatory bodies in 2024.
And of course Ken's comments at the bottom) An elderly obese woman with cardiomyopathy, Left bundle branch block, and chronic hypercapnea presented hypoxic with altered mental status. I do not see OMI here and all trops were only minimally elevated, consistent with either chronic injury from cardiomyopathy or with acute injury from sepsis.
Long-term follow-up (FU) of the TRED-HF trial: persistent high-risk of relapse following therapy withdrawal in recovered dilated cardiomyopathy (DCM), likely contributed to by low-dose therapy and exposure to external triggers. Participants were recommended to restart therapy post-trial and were followed until May 2023.
In July 2023, BridgeBio announced positive results from ATTRibute-CM, reporting a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p p European Society of Cardiology Congress 2023 and at the American Heart Association Scientific Sessions 2023. “As
Introduction The primary concern for women who have experienced peripartum cardiomyopathy (PPCM) is the safety of a subsequent pregnancy (SSP). Methods Three databases (PubMed, Scopus, and ScienceDirect) were used to identify relevant studies prior to 17 October 2023. This study aimed to evaluate the outcomes of SSP in women with PPCM.
As per my review of this subject ( Check out My Comment at the bottom of the page in the November 16, 2023 post in Dr. Smith's ECG Blog ) — the 3 most common Causes of ACS ( A cute C oronary S yndrome ) with a "negative" cath are: i ) Myocarditis; ii ) Takotsubo cardiomyopathy; and , iii ) MINOCA.
On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
4 Demonstrated Impact in Pregnant Women: A clinical study led by Mayo Clinic involving nearly 1,200 pregnant women in Nigeria highlighted the AI's effectiveness, identifying twice as many cases of pregnancy-related cardiomyopathy than standard care, with an impressive AUROC of 0.98, 100.0% 2023, January 5). 2023, January 5).
Although the 2024 ACC/American Heart Association (AHA) and 2023 European Society of Cardiology (ESC) guidelines stratify well overall the risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM).
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 496-506, October 1, 2023. Previous studies on cardiomyopathies have been particularly valuable for clarifying pathological mechanisms in heart failure, an etiologically heterogeneous disease.
Thirty day electrocardiogram (ECG) monitoring in patients with hypertrophic cardiomyopathy (HCM) detects more arrhythmias than the standard 24 to 48 hours, according to late breaking science presented at EHRA 2023, a scientific congress of the European Society of Cardiology (ESC).
Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 452-461, October 1, 2023. When treatable causes are excluded, studies to define causes are often abandoned, resulting in a diagnosis of end-stage idiopathic cardiomyopathy. of patients with unexplained end-stage cardiomyopathy.
As India concludes 2023, the final fortnight of December has witnessed nearly 8,500 Covid-19 cases. It serves as an initial assessment, and an MRI may be considered if other signs of cardiomyopathy are present. On Sunday, the nation reported 841 new instances of COVID-19, marking the most substantial daily increase in over 10 months.
Circulation: Cardiovascular Imaging, Volume 16, Issue 11 , Page e000081, November 1, 2023. Infiltrative cardiomyopathies comprise a broad spectrum of inherited or acquired conditions caused by deposition of abnormal substances within the myocardium. thereby eliminating the need for endomyocardial biopsy in most cases.
Background:Despite the role of cardiac catheterization for hemodynamic assessment and endomyocardial biopsy (EMB) in children with cardiomyopathy, data on procedure-related major adverse events (MAE) in this population is lacking. We aim to describe the rate of MAE in children with cardiomyopathy undergoing cardiac catheterization.
While the spotlight in 2023 shone on developments around Generative Artificial Intelligence (AI), away from the limelight a quiet revolution in AI was taking place, which promises to transform the way we diagnose, manage, and treat cardiovascular diseases, the world’s leading cause of death.
Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heart failure, hypertension, and numerous cardiomyopathies. Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heart failure, hypertension, and numerous cardiomyopathies.
with SmartAssist ; Impella LD Product Codes: See Recall Database Entry Distribution Dates: October 10, 2021 to October 10, 2023 Devices Recalled in the U.S.: Recalled Product US Available Product Names: Impella 2.5; Impella CP; Impella CP with SmartAssist; Impella 5.0;
Image courtesy of UCL Institute of Cardiovascular Science / James Tye milla1cf Tue, 12/19/2023 - 18:19 December 19, 2023 — A vest that can map the electrical activity of the heart in fine detail could potentially be used to better identify people at high risk of sudden cardiac death , suggests a new study led by UCL researchers.
According to a written statement, the GenePHIT trial aims to evaluate the safety and efficacy of a single intracoronary infusion of AB-1002 in adults with New York Heart Association (NYHA) Class III Heart Failure and non-ischemic cardiomyopathy who have been medically stable for at least 4 weeks. Available at: [link] Accessed February 2024.
There was hyperkinesis of the basal segments and findings were interpreted as typical of takotsubo cardiomyopathy. An MRI was deemed unnecessary at the diagnosis of stress cardiomyopathy was concidered certain. Takotsubo cardiomyopathy is not a completely benign disorder. Long QT syndrome may have normal QTc on the ECG.
BACKGROUND:Validly measuring disease-specific health status is critical in patients with severe tricuspid regurgitation (TR) to quantify the benefit of different interventions.
Introduction Heart transplantation (HT) is the only treatment option in children with heart failure secondary to cardiomyopathies and non-reparable congenital heart diseases. 24 patients (88.8%) were diagnosed with dilated cardiomyopathy, 2 (7.4%) with restrictive cardiomyopathy, and 1 (3.7%) with hypertrophic cardiomyopathy.
Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012191, November 1, 2023. BACKGROUND:The cause of hypertrophic cardiomyopathy (HCM) in the young is highly varied. METHODS:Retrospective cohort study of patients <21 years of age with HCM/preexcitation from 2000 to 2022.
Publication date: Available online 13 December 2023 Source: The American Journal of Cardiology Author(s): Andrea Petretta, Alberto Cuocolo, Mario Petretta
This is a very typical ECG for Hypertrophic Cardiomyopathy. The most recent previous was 4 years prior, and was in the normal range) Elderly patients, and patients with cardiomyopathy (including HOCM), may have troponin values in this range chronically ("chronic myocardial injury").
The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members.
Data were collected August 8-September 8, 2023.Results:165 A paired samples t-test was conducted on overall average number of correct responses and for confidence rating, and a McNemar’s test was conducted at the question level (significance level,P< 05).
A 50-something male with unspecified history of cardiomyopathy presented in diabetic ketoacidosis (without significant hyperkalemia) with a wide complex tachycardia and hypotension. The fact that he has a cardiomyopathy argues for a more typical ventricular tachycardia, as does the absence of rSR' in lead V1. It is regular.
Mavacamten is now approved for treatment of symptomatic hypertrophic obstructive cardiomyopathy and endorsed by mult-society guidelines. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy was published in 2023, with 28 patients on aficamten 13 on placebo. 2023 Jan 3;81(1):34-45.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content